Cardiovascular diseases lead to 31.5% of deaths globally, and particularly myocardial infarction (MI) results in 7.4 million deaths per year. Diagnosis of MI and monitoring for prognostic use are critical for clinical management and biomedical research, which require advanced tools with accuracy and speed. Herein, we developed a plasmonic gold nano-island (pGold) chip assay for diagnosis and monitoring of MI. On-chip microarray analysis of serum biomarkers (e.g., cardiac troponin I) afforded up to 130-fold enhancement of near-infrared fluorescence for ultra-sensitive and quantitative detection within controlled periods, using 10 μL of serum only. The pGold chip assay achieved MI diagnostic sensitivity of 100% and specificity of 95.54%, superior to the standard chemiluminescence immunoassay in cardiovascular clinics. Further, we monitored biomarker concentrations regarding percutaneous coronary intervention for prognostic purpose. Our work demonstrated a designed approach using plasmonic materials for enhanced diagnosis and monitoring for prognostic use towards point-of-care testing.

Current metabolic analysis is far from ideal to engage clinics and needs rationally designed materials and device. Here we developed a novel plasmonic chip for clinical metabolic fingerprinting. We first constructed a series of chips with gold nanoshells on the surface through controlled particle synthesis, dip-coating, and gold sputtering for mass production. We integrated the optimized chip with microarrays for laboratory automation and micro-/nanoscaled experiments, which afforded direct high-performance metabolic fingerprinting by laser desorption/ionization mass spectrometry using 500 nL of various biofluids and exosomes. Further we for the first time demonstrated on-chip in vitro metabolic diagnosis of early stage lung cancer patients using serum and exosomes. This work initiates a new bionanotechnology based platform for advanced metabolic analysis toward large-scale diagnostic use.

Bioprinting is an emerging field that utilizes 3D printing technology to fabricate intricate biological structures, including tissues and organs. Among the various promising bioprinting techniques, laser-induced forward transfer (LIFT) stands out by employing a laser to precisely transfer cells or bioinks onto a substrate, enabling the creation of complex 3D architectures with characteristics of high printing precision, enhanced cell viability, and excellent technical adaptability. This technology has found extensive applications in the production of biomolecular microarrays and biological structures, demonstrating significant potential in tissue engineering. This review briefly introduces the experimental setup, bioink ejection mechanisms, and parameters relevant to LIFT bioprinting. Furthermore, it presents a detailed summary of both conventional and cutting-edge applications of LIFT in fabricating biomolecule microarrays and various tissues, such as skin, blood vessels and bone. Additionally, the review addresses the existing challenges in this field and provides corresponding suggestions. By contributing to the ongoing development of this field, this review aims to inspire further research on the utilization of LIFT-based bioprinting in biomedical applications.

The highly sensitive detection and imaging of biomarkers are critical for early diagnosis, treatment, and prognosis monitoring. The unique size and structure of fluorescent nanomaterials provide key benefits such as excellent photostability, high fluorescence quantum yield, and tunable excitation and emission wavelengths. These properties have led to the widespread application of nanomaterials in fluorescent biomarkers detection and imaging. In this review, we began by introducing the composition of fluorescent probes and discussing the underlying sensing mechanisms. We then summarized recent advances in the use of fluorescent nanomaterials such as quantum dots (QDs), metal nanoclusters (MNCs), carbon dots (CDs), and metal-organic frameworks (MOFs) for biomarker detection and imaging. Additionally, we highlighted the applications of fluorescent nanomaterials in the detection and imaging of small molecules, biomacromolecules, and various biomarkers, including metal ions, bacteria, and circulating tumor cells (CTCs). The challenges and future prospects of fluorescent nanomaterials in biomarker detection and imaging were also discussed. We anticipate that fluorescent nanomaterials will have profound implications for clinical biomarker detection and imaging, with considerable application in both academic research and industrial applications.

Hydrogen peroxide (H₂O₂) is a signaling molecule that has the capacity to control a variety of biological processes in organisms. Cancer cells release more H₂O₂ during abnormal tumor growth. There has been a considerable amount of interest in utilizing H₂O₂ as a biomarker for the diagnosis of cancer tissue. In this study, an electrochemical sensor for H₂O₂ was constructed based on 3D reduced graphene oxide (rGO), MXene (Ti₃C₂), and multi-walled carbon nanotubes (MWCNTs) composite. Three-dimensional (3D) rGO–Ti₃C₂–MWCNTs sensor showed good linearity for H₂O₂ in the ranges of 1–60 μM and 60 μM–9.77 mM at a working potential of −0.25 V, with sensitivities of 235.2 µA mM⁻¹ cm⁻² and 103.8 µA mM⁻¹ cm⁻², respectively, and a detection limit of 0.3 µM (S/N = 3). The sensor exhibited long-term stability, good repeatability, and outstanding immunity to interference. In addition, the modified electrode was employed to detect real-time H₂O₂ release from cancer cells and cancer tissue ex vivo.